Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,938 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan.
Sugimoto M, Ito S, Mashima K, Umino K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Ashizawa M, Yamamoto C, Fujiwara S, Okazuka K, Hatano K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kako S, Kanda Y. Sugimoto M, et al. Among authors: kawasaki y. Ann Hematol. 2016 Sep;95(9):1513-9. doi: 10.1007/s00277-016-2740-9. Epub 2016 Jul 1. Ann Hematol. 2016. PMID: 27365141
Relationship between white blood cell count elevation and clinical response after G-CSF priming chemotherapy for acute myeloid leukemia.
Minakata D, Fujiwara SI, Ikeda T, Toda Y, Ito S, Mashima K, Umino K, Nakano H, Yamasaki R, Morita K, Kawasaki Y, Sugimoto M, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y. Minakata D, et al. Among authors: kawasaki y. Int J Hematol. 2017 Sep;106(3):411-417. doi: 10.1007/s12185-017-2251-z. Epub 2017 May 15. Int J Hematol. 2017. PMID: 28508228
Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia.
Fujiwara SI, Shirato Y, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Ochi SI, Nagayama T, Mashima K, Umino K, Minakata D, Nakano H, Morita K, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Yamamoto C, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y. Fujiwara SI, et al. Among authors: kawasaki y. Int J Hematol. 2018 Jun;107(6):712-715. doi: 10.1007/s12185-017-2378-y. Epub 2017 Nov 28. Int J Hematol. 2018. PMID: 29185155
Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies.
Minakata D, Fujiwara SI, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Ochi SI, Nagayama T, Mashima K, Umino K, Nakano H, Yamasaki R, Morita K, Kawasaki Y, Sugimoto M, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Ohmori T, Kanda Y. Minakata D, et al. Among authors: kawasaki y. Int J Hematol. 2019 Feb;109(2):141-146. doi: 10.1007/s12185-018-02567-w. Epub 2018 Dec 8. Int J Hematol. 2019. PMID: 30536180
Comparison of neutropenia profiles in different treatment protocols for acute myeloid leukemia using the D-index.
Kawasaki Y, Kimura SI, Nakano H, Mashima K, Shirato Y, Kawaguchi SI, Toda Y, Ochi SI, Nagayama T, Minakata D, Yamasaki R, Morita K, Ashizawa M, Yamamoto C, Hatano K, Sato K, Oh I, Fujiwara SI, Ohmine K, Kako S, Muroi K, Kanda Y. Kawasaki Y, et al. Int J Hematol. 2019 Apr;109(4):470-476. doi: 10.1007/s12185-019-02593-2. Epub 2019 Jan 25. Int J Hematol. 2019. PMID: 30684252
Impact of prednisolone dosage in the CHOP regimen for follicular lymphoma: a retrospective study.
Ikeda T, Fujiwara SI, Nakajima H, Kawaguchi SI, Toda Y, Ito S, Ochi S, Nagayama T, Mashima K, Umino K, Minakata D, Nakano H, Morita K, Yamasaki R, Kawasaki Y, Ashizawa M, Yamamoto C, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y. Ikeda T, et al. Among authors: kawasaki y. Int J Hematol. 2020 Sep;112(3):369-376. doi: 10.1007/s12185-020-02908-8. Epub 2020 Jun 11. Int J Hematol. 2020. PMID: 32529585
The prognostic significance of rapid peripheral blood blast clearance during the initial course of induction chemotherapy in young patients with de novo acute myeloid leukemia.
Nakano H, Fujiwara SI, Ito S, Mashima K, Umino K, Minakata D, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Yamamoto C, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y. Nakano H, et al. Among authors: kawasaki y. Hematol Oncol. 2017 Sep;35(3):357-364. doi: 10.1002/hon.2277. Epub 2015 Dec 7. Hematol Oncol. 2017. PMID: 26639319
A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis.
Minakata D, Fujiwara S, Ito S, Mashima K, Umino K, Nakano H, Kawasaki Y, Sugimoto M, Yamasaki R, Yamamoto C, Ashizawa M, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y. Minakata D, et al. Among authors: kawasaki y. Leuk Res. 2016 Mar;42:82-7. doi: 10.1016/j.leukres.2015.12.013. Epub 2016 Jan 2. Leuk Res. 2016. PMID: 26790727
Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia.
Yamamoto C, Ito S, Mashima K, Umino K, Minakata D, Yamasaki R, Kawasaki Y, Sugimoto M, Nakano H, Ashizawa M, Okazuka K, Hatano K, Sato K, Oh I, Fujiwara S, Ohmine K, Suzuki T, Muroi K, Kanda Y. Yamamoto C, et al. Among authors: kawasaki y. Leuk Lymphoma. 2016 Nov;57(11):2541-7. doi: 10.3109/10428194.2016.1153087. Epub 2016 Feb 25. Leuk Lymphoma. 2016. PMID: 26917050
1,938 results